Teacher Retirement System of Texas boosted its holdings in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 17.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,735 shares of the medical research company’s stock after buying an additional 1,432 shares during the quarter. Teacher Retirement System of Texas’ holdings in Exact Sciences Corporation were worth $459,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of EXAS. Fred Alger Management Inc. purchased a new position in Exact Sciences Corporation during the second quarter valued at approximately $84,177,000. Lord Abbett & CO. LLC grew its holdings in Exact Sciences Corporation by 59.1% in the second quarter. Lord Abbett & CO. LLC now owns 2,356,706 shares of the medical research company’s stock worth $83,357,000 after purchasing an additional 875,527 shares during the last quarter. Victory Capital Management Inc. purchased a new position in Exact Sciences Corporation in the second quarter worth $29,450,000. Vanguard Group Inc. grew its holdings in Exact Sciences Corporation by 8.0% in the second quarter. Vanguard Group Inc. now owns 9,459,679 shares of the medical research company’s stock worth $334,589,000 after purchasing an additional 700,051 shares during the last quarter. Finally, Green Valley Investors LLC purchased a new position in Exact Sciences Corporation in the second quarter worth $20,892,000. 86.04% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.watchlistnews.com/teacher-retirement-system-of-texas-raises-position-in-exact-sciences-corporation-exas/1721750.html.

Shares of Exact Sciences Corporation (EXAS) opened at $59.17 on Thursday. Exact Sciences Corporation has a one year low of $13.05 and a one year high of $63.60. The company has a current ratio of 10.34, a quick ratio of 9.98 and a debt-to-equity ratio of 0.01.

Exact Sciences Corporation (NASDAQ:EXAS) last posted its quarterly earnings data on Monday, October 30th. The medical research company reported ($0.23) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.07. The business had revenue of $72.60 million during the quarter, compared to the consensus estimate of $65.03 million. Exact Sciences Corporation had a negative net margin of 60.71% and a negative return on equity of 30.32%. The business’s revenue for the quarter was up 158.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.36) earnings per share. equities research analysts forecast that Exact Sciences Corporation will post -1.12 earnings per share for the current fiscal year.

Several research firms have issued reports on EXAS. Lake Street Capital lifted their price target on shares of Exact Sciences Corporation from $30.00 to $41.00 and gave the stock a “hold” rating in a report on Wednesday, July 26th. Roth Capital lifted their price target on shares of Exact Sciences Corporation from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Wednesday, July 26th. Jefferies Group LLC lifted their price target on shares of Exact Sciences Corporation to $60.00 and gave the stock a “buy” rating in a report on Tuesday, October 31st. Robert W. Baird lifted their price target on shares of Exact Sciences Corporation from $49.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 31st. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $45.00 price target on shares of Exact Sciences Corporation in a report on Thursday, September 7th. Eight research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $49.98.

In related news, CEO Kevin T. Conroy sold 137,805 shares of the business’s stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $59.14, for a total transaction of $8,149,787.70. Following the completion of the transaction, the chief executive officer now directly owns 967,867 shares in the company, valued at $57,239,654.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kevin T. Conroy sold 134,057 shares of the business’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $59.50, for a total transaction of $7,976,391.50. The disclosure for this sale can be found here. Insiders have sold 549,235 shares of company stock valued at $28,761,750 over the last 90 days. 4.00% of the stock is currently owned by insiders.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS).

Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.